Oparta (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate binds to glucocorticoid receptors in airway epithelial cells, suppressing the release of inflammatory mediators such as cytokines and chemokines. This anti‑inflammatory action decreases airway swelling, mucus production, and hyper‑responsiveness, helping to keep the airways open and less reactive.

The prescribed dose of Oparta is determined by the treating physician based on the severity of asthma or COPD, patient age, and response to therapy. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety data for Oparta in pregnancy are limited; it should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as small amounts of inhaled corticosteroid may pass into breast milk, but the clinical significance is generally considered low.

To request Oparta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Oparta combines an inhaled corticosteroid with a long‑acting β2‑agonist in a single device, similar to other combination inhalers such as fluticasone/salmeterol. Its specific strengths, particle size and formulation may offer different lung deposition characteristics, but clinical efficacy in controlling asthma and COPD is comparable when used as directed.

Store Oparta at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and direct sunlight. Keep the inhaler cap closed when not in use and avoid exposing it to extreme temperatures that could affect the dose consistency.

Oparta is delivered via a metered‑dose inhaler. The patient inhales a prescribed number of puffs, usually after shaking the device, exhaling fully, and then breathing in slowly and deeply through the mouthpiece, followed by a breath hold for a few seconds. Specific technique instructions are provided by the prescriber.

Serious risks include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, pneumonia, and systemic effects from prolonged corticosteroid exposure like adrenal suppression, osteoporosis, glaucoma, or cataracts. Patients should seek immediate medical attention if they experience sudden breathing difficulty, swelling, or rash.